RALY heterogeneous nuclear ribonucleoprotein (RALY)

RALY is a multifunctional RNA-binding protein member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family. It is primarily involved in numerous aspects of RNA metabolism, including the regulation of mRNA stability, translation, and alternative splicing, thereby influencing gene expression at the post-transcriptional level. RALY binds poly-U rich elements within coding and non-coding RNAs, modulating processes such as RNA processing, splicing, and possibly 3'-end processing[1][2]. It also associates with chromatin—both transcriptionally active and inactive—with interactions partially dependent on RNA, and has been implicated in functioning as a transcriptional co-factor[2]. RALY interacts with several proteins involved in RNA metabolism and translational control, as well as with components of the spliceosome and other RNA-binding proteins[4]. Its expression is up-regulated in various cancers, and its down-regulation impairs cell proliferation and alters the expression of genes involved in cell cycle regulation, immune response, and viral defense[2][3]. RALY has been shown to specifically influence the stability and expression of transcripts such as E2F1, ANXA1, and H1FX, and to regulate the alternative splicing of factors like PRMT1, linking it to oncogenic and chemotherapeutic outcomes[2][3]. While RALY is a plausible therapeutic target due to its functional importance in cancer progression and immune modulation, no drugs directly targeting RALY have been reported to date, and its comprehensive biomarker and safety profile remain to be established.

Other names

RNA-binding protein RalyHNRPCL2P542hnRNP core protein C-like 2Autoantigen p542Heterogeneous nuclear ribonucleoprotein C-like 2hnRNP associated with lethal yellow protein homologRNA-binding protein (autoantigenic)RNA-binding protein (autoantigenic, hnRNP-associated with lethal yellow)